• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Pasithea Therapeutics Corp.

    9/9/25 4:30:40 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KTTA alert in real time by email
    S-8 1 ea0256173-s8_pasithea.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on September 9, 2025

    Registration No. 333-   

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8 

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    PASITHEA THERAPEUTICS CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   85-1591963
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification Number)

     

    1111 Lincoln Road, Suite 500

    Miami Beach, Florida 33139

    (Address of principal executive offices) (Zip code)

     

    Pasithea Therapeutics Corp. 2023 Stock Incentive Plan

    (Full title of the plan)

     

    Dr. Tiago Reis Marques

    Chief Executive Officer

    Pasithea Therapeutics Corp.

    1111 Lincoln Road, Suite 500

    Miami Beach, Florida 33139

    (Name and address of agent for service)

     

    Tel:  (786) 977-3380

    (Telephone number, including area code, of agent for service)

     

    With a copy to:

     

    James O’Grady, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Tel: (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed by the registrant, Pasithea Therapeutics Corp. (the “Company”), for the purpose of registering an additional 1,750,000 shares of common stock, par value $0.0001 per share, of the Company, to be issued under the Pasithea Therapeutics Corp. 2023 Stock Incentive Plan (as amended, effective as of September 3, 2025) (the “2023 Plan”), pursuant to General Instruction E on Form S-8 (Registration of Additional Securities).

     

    The contents of the original registration statement on Form S-8 for the 2023 Plan filed on March 29, 2024 (File No. 333-278386) are hereby incorporated by reference and made a part hereof. Any items in the Company’s Registration Statement on Form S-8 (File No. 333-278386) not expressly changed hereby shall be as set forth in the Company’s Registration Statement on Form S-8 (File No. 333-278386). The stockholders of the registrant approved amending the 2023 Plan for this purpose at the annual meeting of stockholders held on September 3, 2025.

     

    1

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Certain Documents by Reference

     

    The Securities and Exchange Commission allows us to “incorporate” into this registration statement information we file with other documents. This means that we may disclose important information to you by referring to other documents that contain that information. The information incorporated by reference is considered to be part of this registration statement, and information we file later with the Securities and Exchange Commission will automatically update and supersede this information. We incorporate by reference the documents listed below, except to the extent information in those documents is different from the information contained in this registration statement:

     

    ●Our Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 24, 2025.

     

    ●Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed on May 15, 2025.

     

    ●Our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed on August 14, 2025.

     

    ●Our Current Reports on Form 8-K filed with the Securities and Exchange Commission on April 25, 2025, May 7, 2025, June 20, 2025, June 27, 2025, July 11, 2025 and September 3, 2025 (except to the extent furnished but not filed).

     

    ●The description of the Company’s common stock contained in the Company’s Registration Statement on Form 8-A (Registration No. 001-40804) filed with the Securities and Exchange Commission on September 13, 2021 under Section 12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.7 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 29, 2024.

     

    All documents subsequently filed by us with the Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this registration statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

    II-1

     

     

    Item 8. Exhibits

     

    The exhibits accompanying this registration statement are listed on the accompanying exhibit index. 

     

    EXHIBIT INDEX

     

    Exhibit Number   Description
         
    5.1   Opinion of Lowenstein Sandler LLP*
    10.1   Pasithea Therapeutics Corp. 2023 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 19, 2023)
    10.2   Amendment to the Pasithea Therapeutics Corp. 2023 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 3, 2025)
    23.1   Consent of CBIZ CPAs P.C., Independent Registered Public Accounting Firm of Pasithea Therapeutics Corp.*
    23.2   Consent of Lowenstein Sandler LLP (filed as part of Exhibit 5.1)*
    24.1   Power of Attorney (contained on signature page to this registration statement on Form S-8)*
    107   Filing Fee Table*

     

    *Filed herewith.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami Beach, State of Florida, on September 9, 2025.

     

      Pasithea Therapeutics Corp.
       
      By: /s/ Dr. Tiago Reis Marques
      Name: Dr. Tiago Reis Marques
      Title: Chief Executive Officer and Director

     

    KNOW ALL BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Dr. Tiago Reis Marques and Daniel Schneiderman, and each of them singly, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. 

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Dr. Tiago Reis Marques   Chief Executive Officer and Director   September 9, 2025
    Dr. Tiago Reis Marques   (Principal Executive Officer)    
             
    /s/ Daniel Schneiderman   Chief Financial Officer   September 9, 2025
    Daniel Schneiderman   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Prof. Lawrence Steinman   Director   September 9, 2025
    Prof. Lawrence Steinman        
             
    /s/ Simon Dumesnil   Director   September 9, 2025
    Simon Dumesnil        
             
    /s/ Dr. Emer Leahy   Director   September 9, 2025
    Dr. Emer Leahy        
             
    /s/ Alfred Novak   Director   September 9, 2025
    Alfred Novak        

     

    II-3

     

     

    Get the next $KTTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KTTA

    DatePrice TargetRatingAnalyst
    12/14/2021$3.25Buy
    EF Hutton
    More analyst ratings

    $KTTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Steinman Lawrence

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    10/27/25 5:27:18 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Schneiderman Daniel H

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    10/27/25 5:27:02 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Marques Tiago

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    10/27/25 5:26:30 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EF Hutton initiated coverage on Pasithea Therapeutics with a new price target

    EF Hutton initiated coverage of Pasithea Therapeutics with a rating of Buy and set a new price target of $3.25

    12/14/21 8:32:07 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    SEC Filings

    View All

    Pasithea Therapeutics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

    11/4/25 7:04:23 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Corp. filed SEC Form 8-K: Leadership Update

    8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

    10/27/25 5:25:40 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

    9/16/25 7:04:47 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Leadership Updates

    Live Leadership Updates

    View All

    Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

    MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, primary sclerosing cholangitis and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other indic

    6/11/25 7:02:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

    MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other indications, announced today that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company's Scientific Advisory Board. Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology (Division of Neuro-Oncology), Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights

    9/3/24 8:02:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Results from 2023 Annual Meeting

    SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA), today announced that it held its annual meeting of stockholders (the "Annual Meeting") on December 19, 2023. Over 70% of the Company's shares of common stock were represented at the Annual Meeting. More than 95% of shares voted were cast "for" the election of directors (Proposal 1), and over 85% "for" Proposals 2, 3 and 6 (collectively, the "Approved Proposals"). The Approved Proposals related to the following matters: appointment of the Company's proposed slate of directors;-  Dr. Tiago Reis Marques;-  Prof. Larry Steinman;-  Simon Dume

    12/19/23 5:19:00 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Financials

    Live finance-specific insights

    View All

    Pasithea Therapeutics Acquires AlloMek Therapeutics

    -- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) -- Management to Host an Investor Webcast Today at 9 a.m. ET MIAMI BEACH, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it acquired AlloMek Therapeutics, LLC ("AlloMek"), a privately-he

    10/12/22 8:00:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

    - Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth -- Closing consideration of 3.26 million shares of Pasithea common stock -- Pasithea to hold a webcast on June 22 at 9 a.m. ET to discuss the transaction - MIAMI BEACH, Fla., June 22, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), today announced its acquisition of Alpha-5 integrin, LLC ("Alpha-5"), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of am

    6/22/22 8:00:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pasithea Therapeutics Corp.

    SC 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

    11/14/24 3:32:41 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pasithea Therapeutics Corp. (Amendment)

    SC 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

    1/13/23 8:02:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Pasithea Therapeutics Corp. (Amendment)

    SC 13D/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

    1/10/23 3:55:25 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

    MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced activation of a new U.S. clinical trial site at the University of Alabama at Birmingham ("UAB") for its ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patients with neurofibromatosis type 1 (NF1) with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas. The UAB site joins the list of clinical centers participating in the Company's global Phase 1/1b trial, which is designed to assess the safety, tolerab

    11/4/25 7:03:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

    MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced activation of two South Korean clinical trial sites participating in its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004, in adult participants with neurofibromatosis type 1 (NF1) with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas. The South Korea clinical trial sites, ASAN Medical Centre and Severance Hospital Yonsei University Health System,

    9/16/25 7:03:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

    -- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced that the external Safety Review Committee recommended that the Company's Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004, in adult participants with neurofibromatosis type 1 (NF1) should proceed to Cohort 2, 8mg tablet, withou

    9/8/25 7:01:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care